NCT03301129

Brief Summary

Electronic cigarettes (E-cigarettes) and new heat-not-burn tobacco products such as IQOS®, an electronic device that heats a cigarette-like stick without combustion, are a modern and technological surrogate of traditional tobacco cigarettes (T-cigarettes), that are entering in the commercial market. While the negative effects of the traditional cigarette are well known, little data are reported in scientific literature on the risks on the health by these new smoking devices. Endothelial dysfunction evaluated by flow-mediated dilatation (FMD), oxidative stress and platelet activation have been recognized as a hallmark of preclinical systemic atherosclerosis and as a useful marker to stratify the risk of cardiovascular disease in patients at risk or with established clinically significant atherosclerosis. Since no data are reported about the effects of these new smoking device on oxidative stress, platelet activation and FMD, the investigators designed a human study assessing if these new smoking devices have effects on healthy smokers.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2017

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 23, 2017

Completed
11 days until next milestone

First Posted

Study publicly available on registry

October 4, 2017

Completed
11 days until next milestone

Study Start

First participant enrolled

October 15, 2017

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 30, 2018

Completed
26 days until next milestone

Study Completion

Last participant's last visit for all outcomes

February 25, 2018

Completed
Last Updated

March 29, 2018

Status Verified

March 1, 2018

Enrollment Period

4 months

First QC Date

September 23, 2017

Last Update Submit

March 26, 2018

Conditions

Outcome Measures

Primary Outcomes (2)

  • Endothelial dysfunction

    flow-mediated dilatation (FMD) assessed by vascular ultrasound

    up to 24 weeks

  • Oxidative stress

    Soluble Nox2-derived peptide, a direct marker of NADPH oxidase activation

    up to 24 weeks

Secondary Outcomes (1)

  • Platelet activation

    up to 24 weeks

Study Arms (3)

Traditional cigarette

EXPERIMENTAL

smoke one Traditional cigarette (with a mean nicotine content of 0.6 mg according to package label) and in a sub-group smoke a sham cigarette (an traditional cigarette without combustion).

Behavioral: Smoke

Electronic cigarette

EXPERIMENTAL

smoke a tobacco-flavored Electronic cigarette (9 puffs approximately equivalent to 0.6 mg of nicotine content) and in a sub-group smoke a sham cigarette (an electronic cigarette without nicotine).

Behavioral: Smoke

Heat-not-burn tobacco products (IQOS)

EXPERIMENTAL

smoke one IQOS cigarette (with a mean nicotine content of 0.6 mg according to package label).

Behavioral: Smoke

Interventions

SmokeBEHAVIORAL

See arm/group descriptions.

Electronic cigaretteHeat-not-burn tobacco products (IQOS)Traditional cigarette

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Smokers volunteers, minimum age 18 years

You may not qualify if:

  • no history of acute or chronic organic, metabolic and inflammatory diseases;
  • no fever and infections in the last 3 months;
  • no history of cardiovascular pathological symptoms;
  • no allergies;
  • none of the participants took vitamin E, other antioxidant supplements or other drugs potentially affecting oxidative stress or FMD
  • women were not menstruating when the experiment was performed.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sapienza University

Roma, 00161, Italy

Location

Related Publications (1)

  • Biondi-Zoccai G, Sciarretta S, Bullen C, Nocella C, Violi F, Loffredo L, Pignatelli P, Perri L, Peruzzi M, Marullo AGM, De Falco E, Chimenti I, Cammisotto V, Valenti V, Coluzzi F, Cavarretta E, Carrizzo A, Prati F, Carnevale R, Frati G. Acute Effects of Heat-Not-Burn, Electronic Vaping, and Traditional Tobacco Combustion Cigarettes: The Sapienza University of Rome-Vascular Assessment of Proatherosclerotic Effects of Smoking ( SUR - VAPES ) 2 Randomized Trial. J Am Heart Assoc. 2019 Mar 19;8(6):e010455. doi: 10.1161/JAHA.118.010455.

MeSH Terms

Interventions

Smoke

Intervention Hierarchy (Ancestors)

Particulate MatterComplex Mixtures

Study Officials

  • Giacomo Frati, MD

    Sapienza University of Rome, Policlinico Umberto I

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

September 23, 2017

First Posted

October 4, 2017

Study Start

October 15, 2017

Primary Completion

January 30, 2018

Study Completion

February 25, 2018

Last Updated

March 29, 2018

Record last verified: 2018-03

Locations